On 5 December, Unicancer, with the Breast International Group (BIG against breast cancer), Gustave Roussy Transfert, University of Warwick and 22 additional partners – including EUPATI – signed an Grant Agreement for an ambitious new project called #Path4Young, led by Ines Vaz Luis from Gustave Roussy. The goal is to improve care for young women with hormone receptor-positive breast cancer (HR+).
This European Union-funded project, based on the ongoing international multicenterclinical trial OPTIMA (@OPTIMAbstudy), seeks to redefine the care standards for premenopausal women considered at high risk of recurrence.
Today, 25 to 55% of women diagnosed with HR+ and HER2- breast cancer are under 50 years old. While current treatments are effective, these premenopausal women experience more pronounced side effects, especially from chemotherapy, which impacts their long-term quality of life.
The main objectives of the study are:
- Safely de-escalate chemotherapy, guided by a multiparametric test, for young premenopausal patients with HR+HER2- breast cancer.
- Maximize patients’ quality of life through continuous support throughout their treatment journey, while optimizing the use of digital tools and enhancing patient involvement in the project’s implementation.
The Path4Young study plans to recruit 3,380 participants across more than 300 recruitment hospitals in several countries in Europe, Latin America, and Oceania. Patient enrollment is scheduled to begin in June 2025, with follow-ups lasting at least 36 months.
This project represents a major step forward in tailoring breast cancer treatment for young women and providing innovative solutions to better support patients.
EUPATI is a proud partner of this project, and we are eager to contribute our expertise to help improve the quality of life and care of young women with breast cancer.
On January 20 2025, EUPATI Executive Director Maria Dutarte attended the kickoff meeting of the project in Paris.
EUPATI will collaborate with a consortium of 26 partners and play a pivotal role in the Work Package focused on:
🔹 Optimizing patient co-creation and representation
Our contributions will include:
✔️ Supporting patient recruitment for the Patient and Provider Co-Creation Stakeholder Board, ensuring the patient voice is central to the project.
✔️ Delivering expert training in co-design and patient engagement for the consortium.
✔️ Developing a digital course for both patients and healthcare providers on clinical trial operations and the novel care pathway being tested in the trial.
This kickoff marks a key milestone in fostering collaboration and innovation to enhance the quality of life and care for young women with breast cancer. Kickoff meetings are where ideas turn into action, and we’re eager to contribute to the vision and strategy of this groundbreaking project.
Stay tuned for updates from PATH-FOR-YOUNG as we make strides together toward meaningful impact. Learn more here: https://bigagainstbreastcancer.org/official-signing-path-for-young/
Disclaimer: Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them
#Path4Young #Unicancer #CancerResearch #Health #HaDEA #HorizonEU
Date posted: January 22, 2025
Categories: Uncategorized
